spacer
home > pmps > spring 2007 > unmasking the blind of over-encapsulation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Unmasking the Blind of Over-Encapsulation

Richard Shannon at Almac Clinical Services, assesses the impact of over-encapsulation in the clinical supplies industry

A study conducted by the Tufts Center for the Study of Drug Development estimated that the cost of bringing a novel compound to market is in excess of $800 million, so the need to prove superior efficacy and safety when compared to an already marketed product is of critical importance. When developing protocol designs, blinding or masking of clinical supplies is an integral part of many studies. This can help remove both investigator and patient bias due to the visibility of the marketed product, and can limit any potential placebo effect. One of the extensively used mechanisms available to sponsor companies to promote blinding is the over-encapsulation of tablets or capsules.

Over-encapsulation is now a widely accepted mechanism used throughout the clinical supplies industry, and while the process itself may appear relatively straightforward, packaging for clinical supplies is a complex process that is strictly controlled by good manufacturing practice (GMP). The principle of overencapsulation is simply the addition of a product or products to a hard gelatin capsule, which may or may not be backfilled with an inactive bulk agent or excipient. This process can be used for comparator products, investigational medicinal products (IMP) and/or placebos, providing an output of visually identical capsules for each product or strength, thus maintaining the blind and removing any potential bias.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Richard Shannon joined Almac Clinical Services (formerly Clinical Trial Services) in 1999 and has served in various business development functions during this time. He began his Almac career in Europe, before relocating to Almac, US, in 2001, where he gained valuable insight into the US clinical trial supply market and was integral in establishing a new business development team. Richard returned to Almac Europe in October 2005, and was appointed Head of Business Development (Europe). Prior to joining Almac, Richard was employed by MDS Harris (now MDS Pharmaservices) where he performed various clinical trial conduct roles. Richard holds a BSc (Hons) from Queen’s University, Belfast.
spacer
Richard Shannon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>

 
Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals – gaining strong, new industry contacts and building on existing ones.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement